WeChat Mini Program
Old Version Features

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline,Amitkumar Mehta,Tycel Phillips,Lapo Alinari,Alexey V. Danilov,Stephane Doucet,Steven I. Park,Deborah Berg,Alejandro Gomez-Pinillos,Alonzo Martinez,Bo Chao,Allison J. Berger,John Gibbs,Sharon Friedlander,Christine K. Ward,Igor Proscurshim,Brenda W. Cooper,Paolo F. Caimi

Blood（2021）

Cited 4|Views21
Key words
SUMOylation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined